or
Bookmark and Share
Biological preparations
   
Document Number
US Patent 4196191
Issued Date
April 1, 1980
Link
Inventors
Map
Abstract
A novel antigenic preparation which comprises a plurality of microvesicles which microvesicles are unilamellar bodies comprising a single lipid bilayer upon the exterior surface of which is bound an antigenic protein derived from a virus and having a hydrophobic region.
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
21
Comments:
no comments yet
Owner
Burroughs Wellcome Co. (Research Triangle Park, NC)
Published
April 1, 1980
Application Number
06/025,614
Filed
March 30, 1979
US Classification
424/450   424/196.11 424/210.1 424/212.1 424/221.1 424/229.1 424/230.1 424/283.1 424/812
Int'l Classification
A61K   9/127   (20060101)   A61K   39/00   (20060101)   A61K   39/39   (20060101)  
Examiner
Attorney/Law Firm
Parent Case
This application is a continuation of application Ser. No. 882,445, dated Mar. 1, 1978, (now U.S. Pat. No. 4,148,876) which is in turn a continuation-in-part of application Ser. No. 727,610, dated Sept. 28, 1976 (now abandoned).
Priority Data
Sep 29, 1975 [GB] 39857/75
USPTO Field of Search
424/89  
Related Patents
4661346 - Immunological compositions including a peptide and osmium or ruthenium tetroxide - Owned by National Research Development Corporation (GB2)

Immunogenic compositions comprising a peptide or protein material together with an oxide selected from the group consisting of osmium tetroxide, potassium permanganate and ruthenium oxide, and antibodies raised by the use of such a composition, are of value in therapy and diagnosis, for example in the context of snake venom vaccines.

4790987 - Viral glycoprotein subunit vaccine - Owned by Research Corporation (New York, NY)

The present invention relates to a vaccine composition useful in preparation of virus-caused disease comprising as its active agent at least one immunogenically effective amount of immunogenic viral envelope glycoprotein complexed with a lipid.

6096291 - Mucosal administration of substances to mammals - Owned by Biovector Therapeutics, S.A. (Labege Cedex,FR)

A novel method for the mucosal administration of a substance to a mammal is provided. The method comprises contacting a mucosal surface of the mammal with the substance in combination with a Biovector. The Biovector has a core that comprises a natural polymer, or a derivative or a hydrolysate of a natural polymer, or a mixture thereof. A preferred natural polymer is a polysaccharide or an oligosaccharide. The core is optionally coated with an amphiphilic compound, such as a lipid.

6017513 - Mucosal administration of substances to mammals - Owned by Biovector Therapeutics, S.A. (Labege Cedex,FR)

A novel method for the mucosal administration of a substance to a mammal is provided. The method comprises contacting a mucosal surface of the mammal with the substance in combination with a Biovector. The Biovector has a core that comprises a natural polymer, or a derivative or a hydrolysate of a natural polymer, or a mixture thereof. A preferred natural polymer is a polysaccharide or an oligosaccharide. The core is optionally coated with an amphiphilic compound, such as a lipid.

4663161 - Liposome methods and compositions

The present disclosure relates to novel liposome compositions and methods for their preparation. Utilization of the present invention provides an efficient reconstitution of membrane proteins into large (0.1 to 2 micron diameter) phospholipid vesicles with a large, internal aqueous space. The method has been exemplified with the use of glycoproteins of influenza (A/PR8/34) and Sendai (parainfluenza type I) viruses.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us